Skip to content
HCN Grants Est. 2026
No. HT942526OCRPCTA · Defense Health Agency Contracting Activity - DHACA
Open

DoW Ovarian Cancer, Clinical Trial Award

Dealbreakers No cost share required Audit: not stated Reimbursement-only: not stated
Invitation only
“full application submission is by invitation only.” — From the announcement

At a glance

The Ovarian Cancer Research Program includes awards for clinical trials, investigator-initiated research, early-career academy awards, and pilot research. Eligible applicants range from postdoctoral or clinical fellows to assistant professors and independent investigators at academic levels, depending on the mechanism; some awards require a mentor and some are limited to early-career investigators within 5 or 12 years of their last postdoctoral or clinical fellowship. Funding ranges from $350,000 total costs for 2 years for the Pilot Award to up to $2.8 million total costs for 4 years for the Clinical Trial Award, with other mechanisms capped between $1.05 million and $1.4 million over 4 years. Some awards require preliminary data, some do not allow clinical trials, and several require a letter of intent or preproposal before the full application. The announcement does not state any geographic restriction or cost-share requirement.

AI-generated summary — verify against the announcement

What it funds

  • Science and Technology and other Research and Development
  • Research & Discovery
  • Patients & People with Health Conditions
  • Biomedical & Disease Research
Official description from grants.gov

Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer. Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

Who can apply

  • Unrestricted
Geographic restriction None found in the announcement — likely nationwide